Recent advancements in pharmaceutical approvals, pediatric health challenges, and the evolving role of technology in clinical care define today's medical landscape.
Key Points
The FDA has approved Efsitora, a new once-weekly basal insulin injection, providing an additional long-acting treatment option for patients with type 2 diabetes.
The MHRA has authorized the use of lurbinectedin in combination with atezolizumab as a new maintenance therapy for adults diagnosed with extensive-stage small cell lung cancer.
Lirafugratinib has received FDA approval as a new FGFR2 inhibitor, expanding the market of tyrosine kinase inhibitors available for treating cholangiocarcinoma.
New data indicates that taste aversion is as significant a factor as clinical adverse reactions in leading children to discontinue oral immunotherapy for food allergies.
Hospital admissions for child tooth decay have risen significantly in the UK, with nearly 22,000 children aged five to nine requiring care amid gaps in NHS dental access.
A nationwide survey of US adolescents highlights that experiences of online harassment and exposure to unwanted content differ significantly depending on the social media platform used.
The medical community is actively debating the USPSTF's historic composition, which prioritizes primary care specialists and evidence-evaluation experts over narrow subspecialists.
Artificial intelligence continues to transform ophthalmology, building on early diagnostic breakthroughs to become one of the most rapidly evolving fields for medical AI integration.